NCE-1 Intelligence & Market Opportunity

Qelbree

Viloxazine

CNS agent

Oral Capsule, Extended Release

Approval Date

04-Feb-21

NCE-1 Date

04-Feb-25

NCE Date

04-Feb-26

Commercial snapshot

Market performance & projections

Revenue ($M)

305

CAGR (%)

0.1604

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

364

2027

425

2028

490

2029

553

2030

621

2031

690

2032

750

Molecule profile

Details & specifications

Molecule

Viloxazine

Innovator

SUPERNUS PHARMACEUTICALS, INC

Dosage Form

Oral Capsule, Extended Release

Strength

EQ 200 mg base, EQ 100 mg base, EQ 150 mg base

Therapeutic Category

CNS agent

Usage

To treat attention deficit hyperactivity disorder

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.